FDA Approval Activities for this Drug
Detrol LA Extended
Release Capsules, Pharmacia and Upjohn NDA 21-228/S4 7/21/03 7/28/03
Detrol LA Capsules, 2 and 4 mg extended release, Pharmacia and Upjohn NDA 21-228/S1 4/27/01 5/1/03
Detrol LA Capsules, 2 and 4 mg extended release, Pharmacia and Upjohn NDA 21-228 12/22/00 1/9/01 1/9/01
Detrol Indications: overactive bladder with symptoms of urge urinary incontinence, urgency and frequency
Detrol (Tolterodine Tartrate) Tablets, Pharmacia and Upjohn NDA 20-771/S-010 7/21/03 7/28/03
Detrol (Tolterodine Tartrate) Tablets, 1 and 2 mg, Pharmacia and Upjohn NDA 20-771/S-004 4/6/01 4/9/01 4/9/01
Detrol (Tolterodine Tartrate), 1 and 2 mg Pharmacia and Upjohn NDA 20-771 Detrol LA Extended Release Capsules, Pharmacia and Upjohn | Detrol LA (tolterodine tartrate) Tablets, Pfizer Global, Labeling Revision | Tolterodine Tartrate Tablets, Ranbaxy, Tentative Approval | Detrol (tolterodine tartrate), tablets, Pfizer, Labeling Revision | Detrol LA (tolterodine tartrate) extended release capsules, Pfizer, Efficacy Supplement w/Clinical Data | Detrol (tolterodine tartrate) Tablets, Pfizer, Labeling Revision | Detrol LA (tolterodine tartrate) Extended Release Capsules, Pfizer, Labeling Revision | Detrol (tolterodine tartrate) Tablets, Pfizer Global Pharmaceuticals, Labeling Revision | Detrol LA (tolterodine tartrate) Extended-Release Capsules, Pfizer Global Pharmaceuticals, Labeling Revision